Drugs that contain Tafamidis
1. Drug name - VYNDAMAX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7214695 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Apr, 2024
(1 year, 6 months from now) | |
| US9770441 | FOLDRX PHARMS | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole |
Aug, 2035
(12 years from now) | |
| CN100448852C | FOLDRX PHARMS | Stable Thyroxine Carrier Protein And Compositions And Methods For Inhibiting Transthyretin Misfolding Lipocalin. |
Dec, 2023
(1 year, 2 months from now) | |
| CN1747965A | FOLDRX PHARMS | Stabilizing Transthyretin And Inhibiting Transthyretin Protein Misfolding Of Composition And Method |
Dec, 2023
(1 year, 2 months from now) | |
| CN101413143B | FOLDRX PHARMS | Stable Thyroxine Carrier Protein And Compositions And Methods For Inhibiting Transthyretin Misfolding Lipocalin. |
Dec, 2023
(1 year, 2 months from now) | |
| CN101413143A | FOLDRX PHARMS | Compositions And Methods For Stabilising Transthyretin And Inhibiting Transthyretin Misfolding |
Dec, 2023
(1 year, 2 months from now) | |
| IN230323B | FOLDRX PHARMS | A Compound For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding |
Dec, 2023
(1 year, 2 months from now) | |
| IN200501588P4 | FOLDRX PHARMS | Composition And Methods For Stablizing Transthyretin And Inhibiting Transthyretin Misfolding |
Dec, 2023
(1 year, 2 months from now) | |
| EP2325651A3 | FOLDRX PHARMS | Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding |
Dec, 2023
(1 year, 2 months from now) | |
| EP1988397B8 | FOLDRX PHARMS | Compositions And Uses For Stabilising Transthyretin And Inhibiting Transthyretin Misfolding |
Dec, 2023
(1 year, 2 months from now) | |
| EP2325651A2 | FOLDRX PHARMS | Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding |
Dec, 2023
(1 year, 2 months from now) | |
| EP2325651B1 | FOLDRX PHARMS | Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding |
Dec, 2023
(1 year, 2 months from now) | |
| EP1988397A1 | FOLDRX PHARMS | Compositions And Uses For Stabilising Transthyretin And Inhibiting Transthyretin Misfolding |
Dec, 2023
(1 year, 2 months from now) | |
| EP1988397B1 | FOLDRX PHARMS | Compositions And Uses For Stabilising Transthyretin And Inhibiting Transthyretin Misfolding |
Dec, 2023
(1 year, 2 months from now) | |
| EP1587821A4 | FOLDRX PHARMS | Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding |
Nov, 2026
(4 years from now) | |
| EP1587821A2 | FOLDRX PHARMS | Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding |
Nov, 2026
(4 years from now) | |
| EP1587821B1 | FOLDRX PHARMS | Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding |
Nov, 2026
(4 years from now) | |
| EP3191461B1 | FOLDRX PHARMS | Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole |
Aug, 2035
(12 years from now) | |
| EP3191461A1 | FOLDRX PHARMS | Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole |
Aug, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214696 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2023
(1 year, 2 months from now) | |
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Dosage: CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 61MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.